(Japanese) Supporting next generation therapies across diverse modalities
Biopharma innovation is rapidly expanding across diverse modalities, driving increased demand for fully integrated development and manufacturing capabilities.
In a recent feature by Yakuji Nippo, a pharmaceutical industry publication in Japan, Samsung Biologics highlights how its integrated CDMO services support clients across the entire development lifecycle.
Key highlights from the article include:
✅ End-to-end support spanning early development through to commercial manufacturing
✅ Flexible and scalable operations enabling consistent, high-quality production across diverse modalities
✅ Continued strategic investments to meet evolving market demand, including the expansion of our ADC drug product capabilities
Biopharma innovation is rapidly expanding across diverse modalities, driving increased demand for fully integrated development and manufacturing capabilities.
In a recent feature by Yakuji Nippo, a pharmaceutical industry publication in Japan, Samsung Biologics highlights how its integrated CDMO services support clients across the entire development lifecycle.
Key highlights from the article include:
✅ End-to-end support spanning early development through to commercial manufacturing
✅ Flexible and scalable operations enabling consistent, high-quality production across diverse modalities
✅ Continued strategic investments to meet evolving market demand, including the expansion of our ADC drug product capabilities
Share article
Related Content